Blog

All articles

1. 01 Dissociation rate drives binding affinity differences among optimized cetuximab-derived EGFR binders 30 September 2026

   We went back to the raw surface plasmon resonance data behind our results in the 2026 EGFR/cetuximab binder competition, where 3 of our 10 designs surpassed the previous world best. 7 designs bind more tightly than the starting antibody, the 10 split into a strong group and a weak group, and our top design lets go of its target most slowly. The exact binding constants, the order among the best designs and how much tighter they bind than the parent or the published designs need a follow-up experiment.

   
2. 02 Two Scientific Innovators, One Shared Mission 30 July 2026

   We welcome Dr. Shen Yan to Interlit as co-founder, Chief Scientific Officer (CSO), and business developer. With extensive experience in life sciences and innovation-driven initiatives, and as a PhD with an MBA, Dr. Yan bring a unique combination of scientific rigor and business acumen. She will help drive Interlit’s scientific and commercial strategy, translating cutting-edge protein design into clinically relevant and commercially viable solutions.

   
3. 03 The Score Most People Use to Rank Protein Binders Doesn’t Predict Binding 18 July 2026

   For the 2026 EGFR/cetuximab binder optimization competition, we developed a new in silico method to avoid co-folding confidence metrics such as ipTM and ipSAE. Why? Because when ranked by ipSAE, the tightest binder the wet lab validated (which our in silico method also ranked first) would not even have made our top-ten design shortlist.

   
4. 04 In Under a Day, We Set Three World Records in Protein Design 14 July 2026

   A two-person team I led ranked ten candidates in the 2026 EGFR/cetuximab binder optimization competition. All ten bound in the lab, and the one we ranked first proved to be the tightest binder measured.